Likewise, genetically proxied total testosterone was associated with overall (OR:1.15, 95% CI:1.10–1.21, p = 9.39x10−9), luminal A-like (OR:1.22, 95% CI:1.15–1.30, p = 5.80x10−11), and luminal B HER2 negative-like breast cancer risk (OR:1.23, 95% CI:1.13–1.34, p = 1.02x10−6) (Figure 5, Table S6). Here, ERBB2 is linked to breast cancer.